10-Q: NovoCure Q2 2026 Results Show Revenue Growth Amidst R&D Investment

NovoCure Limited reported a 16% increase in net revenues for Q2 2026, driven by patient growth and new product contributions, while managing operating expenses and investing in future development.

Summary

• NovoCure Limited reported net revenues of $183.6 million for the three months ended June 30, 2026, a 16% increase compared to the same period in 2025.
• The company experienced a net loss of $15.7 million for the quarter, an improvement from the $40.1 million loss in Q2 2025.
• Active patient growth was 18% globally for the quarter, contributing to revenue increases in both the United States and international markets.
• Cost of revenues decreased by 1% due to efficiencies and a tariff refund, leading to an improved gross margin of 78% compared to 74% in the prior year.
• Research, development, and clinical study expenses decreased by 8% to $51.4 million, while sales and marketing expenses increased by 8% to $61.7 million.
• General and administrative expenses decreased by 9% to $39.9 million, largely due to a significant decrease in share-based compensation.
• The company ended the quarter with $440.6 million in cash, cash equivalents, and short-term investments, which it believes is sufficient for at least the next 12 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with strong revenue growth and improved gross margins, but tempered by continued net losses and the potential need for future capital raises.

Positives

• Net revenues increased by 16% to $183.6 million in Q2 2026 compared to Q2 2025.
• Global active patient growth was 18% in Q2 2026.
• Gross margin improved to 78% in Q2 2026 from 74% in Q2 2025, driven by revenue growth and cost efficiencies.
• Cost of revenues decreased by 1% due to efficiencies and a tariff refund.
• Net loss improved to $15.7 million in Q2 2026 from $40.1 million in Q2 2025.
• Adjusted EBITDA turned positive, reaching $10.8 million in Q2 2026 from a loss of $9.9 million in Q2 2025.
• Revenues from Optune Lua and Optune Pax showed significant growth, contributing $5.4 million and $1.6 million respectively in Q2 2026.

Negatives

• The company reported a net loss of $15.7 million for the quarter.
• Operating income was a loss of $10.6 million for the quarter.
• Financial income (expenses), net, shifted from a $4.5 million income in Q2 2025 to a $1.9 million expense in Q2 2026.
• The company may need to raise additional capital in the future due to expected increases in operating expenses outpacing gross profit.

Risks

• The company's supply chain in Israel may face distribution and service risks due to the ongoing conflict, although increased stock levels and efforts to secure second-source suppliers are in place.
• Continued volatility in the global tariff environment could potentially impact the company negatively.
• The company may need to raise additional capital to fund operations if operating expenses outpace gross profit.
• The company's ability to secure and maintain coverage from third-party payers for its products is crucial for revenue generation.
• The company's future success depends on obtaining regulatory approvals for new indications and market acceptance of its products.

Future Outlook

The company anticipates continued increases in operating expenses over the next several years, potentially outpacing gross profit, as it expands into additional indications. This may necessitate raising additional capital. The company is exploring options to modify its LUNAR-2 trial design to compress timelines and reduce costs, and anticipates engaging with regulators regarding potential protocol revisions.

Management Comments

• We believe the physical mechanisms of action behind TTFields therapy may be broadly applicable to solid tumor cancers.
• We intend to take actions that prioritize growth and maintain financial health and flexibility as we position our company for future profitability.
• We believe our cash, cash equivalents and short-term investments as of June 30, 2026 are sufficient for our operations for at least the next 12 months based on our existing business plan and our ability to control the timing of significant expense commitments.

Industry Context

StockSavvy.ai notes that NovoCure's performance in Q2 2026 reflects the broader trend in the oncology sector of increasing investment in R&D for novel therapies, alongside the challenges of navigating complex reimbursement landscapes and global supply chain dynamics.

Comparison to Industry Standards

• NovoCure's gross margin of 78% is strong, particularly for a medical device company in the oncology space, though direct comparisons are difficult without specific product category benchmarks.
• The company's net loss of $15.7 million in Q2 2026, while significant, represents an improvement from the prior year, indicating progress towards profitability which is a key focus for many growth-stage biotech and medical device firms.
• The 18% year-over-year active patient growth is a positive indicator of market adoption, a critical metric for companies commercializing new medical technologies.

Legal Proceedings

• The company is involved in various legal proceedings, claims, investigations, and litigation in the ordinary course of business, but management believes the ultimate disposition will not materially affect its financial position or results of operations.

Related Party Transactions

• The company has a License and Collaboration Agreement with Zai Lab (Shanghai) Co., Ltd. ('Zai') to market Optune in Greater China.

Stakeholder Impact

• Shareholders: Continued investment in R&D and new market expansion may lead to future growth, but ongoing losses and potential capital raises present risks.
• Employees: Share-based compensation remains a significant expense, indicating a focus on employee incentives.
• Customers (Patients): Continued development and commercialization of TTFields therapy offer potential new treatment options for cancer patients.
• Payers: The company is actively working to establish coverage policies, which is critical for revenue realization.

Next Steps

• Complete enrollment in the Phase 3 KEYNOTE D58 trial in GBM by the end of 2026.
• Anticipate expanding the clinical pipeline to study TTFields therapy for existing and additional solid tumor indications.
• Engage with regulators regarding potential protocol revisions for the LUNAR-2 trial to streamline endpoints and reduce sample size.
• Continue to pursue coverage policies with payers to expand access to products.
• Begin certifying prescribing physicians for Optune Pax in Germany in July.

Key Dates

Recommendation

The company demonstrates solid revenue growth and operational improvements, including better gross margins and a positive Adjusted EBITDA. However, the continued net loss and the stated potential need for future capital raises suggest a 'hold' recommendation, balancing the positive operational momentum against financial risks and the need for further de-risking of clinical and commercial pathways.

Keywords

Tumor Treating Fields, TTFields, NovoCure, Optune, Oncology, Glioblastoma, Pancreatic Cancer, Lung Cancer